Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 487

1.

Thyroid Tumor Capsular Invasion: the Bottom Line or Much Ado About Nothing?

Mete O, Asa SL.

Endocr Pathol. 2020 Mar 24. doi: 10.1007/s12022-020-09621-6. [Epub ahead of print] No abstract available.

PMID:
32212065
2.

Images in Endocrine Pathology: High-Grade Intrathyroidal Parathyroid Carcinoma with Crooke's Hyalinization.

Yan M, Roncin KL, Wilhelm S, Wasman JK, Asa SL.

Endocr Pathol. 2020 Mar 7. doi: 10.1007/s12022-020-09613-6. [Epub ahead of print] No abstract available.

PMID:
32146582
3.

Syndrome of Inappropriate Antidiuresis in a Young Adult-Searching for the Causative Needle in the Proverbial Haystack.

Gudsoorkar PS, Asa SL, Silverman M.

Kidney Int Rep. 2019 Nov 6;5(2):231-234. doi: 10.1016/j.ekir.2019.10.010. eCollection 2020 Feb. No abstract available.

4.

Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution.

Asa SL, Asioli S, Bozkurt S, Casar-Borota O, Chinezu L, Comunoglu N, Cossu G, Cusimano M, Delgrange E, Earls P, Ezzat S, Gazioglu N, Grossman A, Guaraldi F, Hickman RA, Ikeda H, Jaffrain-Rea ML, Karavitaki N, Kraljević I, La Rosa S, Manojlović-Gačić E, Maartens N, McCutcheon IE, Messerer M, Mete O, Nishioka H, Oz B, Pakbaz S, Pekmezci M, Perry A, Reiniger L, Roncaroli F, Saeger W, Söylemezoğlu F, Tachibana O, Trouillas J, Turchini J, Uccella S, Villa C, Yamada S, Yarman S.

Pituitary. 2019 Dec 13. doi: 10.1007/s11102-019-01015-0. [Epub ahead of print] No abstract available.

PMID:
31834538
5.

The Clinicopathological Spectrum of Acromegaly.

Akirov A, Asa SL, Amer L, Shimon I, Ezzat S.

J Clin Med. 2019 Nov 13;8(11). pii: E1962. doi: 10.3390/jcm8111962. Review.

6.

The Clinicopathological Spectrum of Parathyroid Carcinoma.

Akirov A, Asa SL, Larouche V, Mete O, Sawka AM, Jang R, Ezzat S.

Front Endocrinol (Lausanne). 2019 Oct 23;10:731. doi: 10.3389/fendo.2019.00731. eCollection 2019.

7.

Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.

Thomas CM, Asa SL, Ezzat S, Sawka AM, Goldstein D.

Curr Oncol. 2019 Oct;26(5):338-344. doi: 10.3747/co.26.5539. Epub 2019 Oct 1. Review.

8.

Hypothalamic Endocrine Tumors: An Update.

Asa SL, Mete O.

J Clin Med. 2019 Oct 20;8(10). pii: E1741. doi: 10.3390/jcm8101741. Review.

9.

2020 Vision of Digital Pathology in Action.

Asa SL, Bodén AC, Treanor D, Jarkman S, Lundström C, Pantanowitz L.

J Pathol Inform. 2019 Aug 14;10:27. doi: 10.4103/jpi.jpi_31_19. eCollection 2019. No abstract available.

10.

A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology.

Singarayer R, Mete O, Perrier L, Thabane L, Asa SL, Van Uum S, Ezzat S, Goldstein DP, Sawka AM.

Endocr Pathol. 2019 Sep;30(3):201-218. doi: 10.1007/s12022-019-09585-2.

PMID:
31300997
11.

VEGFR-2 is downregulated in sestamibi-negative parathyroid adenomas.

Erovic BM, Goldstein DP, Asa SL, Janik S, Mete O, Irish JC.

Head Neck. 2019 Oct;41(10):3564-3569. doi: 10.1002/hed.25871. Epub 2019 Jul 10.

PMID:
31291025
12.

Treatment Options for Pancreatic Neuroendocrine Tumors.

Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S.

Cancers (Basel). 2019 Jun 14;11(6). pii: E828. doi: 10.3390/cancers11060828. Review.

13.

Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease.

Bongers PJ, Kluijfhout WP, Verzijl R, Lustgarten M, Vermeer M, Goldstein DP, Devon K, Rotstein LE, Asa SL, Brierley JD, Tsang RW, Ezzat S, Vriens MR, Mete O, Pasternak JD.

Ann Surg Oncol. 2019 Aug;26(8):2533-2539. doi: 10.1245/s10434-019-07444-2. Epub 2019 May 21.

PMID:
31115855
14.

A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.

O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ.

Br J Cancer. 2019 Jun;120(12):1113-1119. doi: 10.1038/s41416-019-0474-x. Epub 2019 May 20.

PMID:
31105270
15.

Characterization of Pancreatic Cancer Tissue Using Multiphoton Excitation Fluorescence and Polarization-Sensitive Harmonic Generation Microscopy.

Tokarz D, Cisek R, Joseph A, Golaraei A, Mirsanaye K, Krouglov S, Asa SL, Wilson BC, Barzda V.

Front Oncol. 2019 Apr 17;9:272. doi: 10.3389/fonc.2019.00272. eCollection 2019.

16.

Ki67 Quantitative Interpretation: Insights using Image Analysis.

Volynskaya Z, Mete O, Pakbaz S, Al-Ghamdi D, Asa SL.

J Pathol Inform. 2019 Mar 8;10:8. doi: 10.4103/jpi.jpi_76_18. eCollection 2019.

17.

Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging.

Turk AT, Asa SL, Baloch ZW, Faquin WC, Fellegara G, Ghossein RA, Giordano TJ, LiVolsi VA, Lloyd R, Mete O, Rosai J, Suster S, Thompson LDR, Wenig BM.

Thyroid. 2019 May;29(5):619-624. doi: 10.1089/thy.2018.0286. Epub 2019 Apr 27.

PMID:
30913992
18.

Somatostatin Receptor Ligand Therapy-A Potential Therapy for Neurocytoma.

Zhang D, Kim SSR, Kelly DF, Asa SL, Movassaghi M, Mareninov S, Yong WH, Cloughesy TF, Rodriguez FJ, McKeever P, Qian J, Li JY, Mao Q, Newell KL, Green RM, Welsh CT, Xiong Z, Heaney AP.

J Clin Endocrinol Metab. 2019 Jun 1;104(6):2395-2402. doi: 10.1210/jc.2018-02419.

PMID:
30722009
19.

The Current Histologic Classification of Thyroid Cancer.

Asa SL.

Endocrinol Metab Clin North Am. 2019 Mar;48(1):1-22. doi: 10.1016/j.ecl.2018.10.001. Review.

PMID:
30717895
20.

An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Alshaikh OM, Asa SL, Mete O, Ezzat S.

Endocr Pathol. 2019 Jun;30(2):118-127. doi: 10.1007/s12022-019-9568-5.

PMID:
30706322
21.

Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon.

Tordjman KM, Greenman Y, Ram Z, Hershkovitz D, Aizenstein O, Ariel O, Asa SL.

Endocr Pathol. 2019 Mar;30(1):74-80. doi: 10.1007/s12022-018-9562-3.

PMID:
30610567
22.

Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion.

Alharbi N, Asa SL, Szybowska M, Kim RH, Ezzat S.

Front Endocrinol (Lausanne). 2018 Nov 1;9:641. doi: 10.3389/fendo.2018.00641. eCollection 2018.

23.

GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.

Mete O, Kefeli M, Çalışkan S, Asa SL.

Mod Pathol. 2019 Apr;32(4):484-489. doi: 10.1038/s41379-018-0167-7. Epub 2018 Nov 2.

24.

Hypothalamic Vasopressin-Producing Tumors: Often Inappropriate Diuresis But Occasionally Cushing Disease.

Asa SL, Ezzat S, Kelly DF, Cohan P, Takasumi Y, Barkhoudarian G, Heaney AP, Ridout R, Chik CL, Thompson LDR, Gentili F, Mete O.

Am J Surg Pathol. 2019 Feb;43(2):251-260. doi: 10.1097/PAS.0000000000001185.

PMID:
30379651
25.

An Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory Carcinoma.

Asa SL, Mete O.

Front Endocrinol (Lausanne). 2018 Sep 25;9:555. doi: 10.3389/fendo.2018.00555. eCollection 2018.

26.

The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations.

Asa SL, Ezzat S, Mete O.

J Clin Med. 2018 Sep 13;7(9). pii: E280. doi: 10.3390/jcm7090280. Review.

27.

Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.

Mete O, Alshaikh OM, Cintosun A, Ezzat S, Asa SL.

Endocr Pathol. 2018 Dec;29(4):332-338. doi: 10.1007/s12022-018-9545-4.

PMID:
30215160
28.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA.

Mod Pathol. 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23.

29.

Retraction for Wei et al., "The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-κB Signaling".

Wei W, Liu W, Cassol CA, Zheng W, Asa SL, Ezzat S.

Mol Cell Biol. 2018 Jul 30;38(16). pii: e00298-18. doi: 10.1128/MCB.00298-18. Print 2018 Aug 15. No abstract available.

30.

Immunohistochemical Biomarkers in Thyroid Pathology.

Baloch Z, Mete O, Asa SL.

Endocr Pathol. 2018 Jun;29(2):91-112. doi: 10.1007/s12022-018-9532-9. Review.

PMID:
29744727
31.

Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Mete O, Asa SL, Giordano TJ, Papotti M, Sasano H, Volante M.

Endocr Pathol. 2018 Jun;29(2):137-149. doi: 10.1007/s12022-018-9525-8. Review.

PMID:
29542002
32.

Immunohistochemical Biomarkers in Pituitary Pathology.

Asa SL, Mete O.

Endocr Pathol. 2018 Jun;29(2):130-136. doi: 10.1007/s12022-018-9521-z. Review.

PMID:
29453601
33.

Epidemiology and biomarker profile of pituitary adenohypophysial tumors.

Mete O, Cintosun A, Pressman I, Asa SL.

Mod Pathol. 2018 Jun;31(6):900-909. doi: 10.1038/s41379-018-0016-8. Epub 2018 Feb 12.

34.

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Trading Six for a Risky Half Dozen: Reply.

Parente DN, Bongers PJ, Verzijl R, Rotstein LE, Asa SL, Kluijfhout WP, Devon KM, Goldstein DP, Mete O, Pasternak JD.

World J Surg. 2018 Jul;42(7):2279. doi: 10.1007/s00268-018-4505-1. No abstract available.

PMID:
29396615
35.

The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Lloyd RV, Asa SL, LiVolsi VA, Sadow PM, Tischler AS, Ghossein RA, Tuttle RM, Nikiforov YE.

Hum Pathol. 2018 Apr;74:1-4. doi: 10.1016/j.humpath.2017.12.027. Epub 2018 Jan 16. No abstract available.

PMID:
29339178
36.

What's new in pituitary pathology?

Asa SL, Mete O.

Histopathology. 2018 Jan;72(1):133-141. doi: 10.1111/his.13295. Review.

PMID:
29239033
37.

Endocrine pathology: past, present and future.

Asa SL, Mete O.

Pathology. 2018 Jan;50(1):111-118. doi: 10.1016/j.pathol.2017.09.003. Epub 2017 Nov 11. Review.

PMID:
29132721
38.

Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?

Hernandez-Prera JC, Machado RA, Asa SL, Baloch Z, Faquin WC, Ghossein R, LiVolsi VA, Lloyd RV, Mete O, Nikiforov YE, Seethala RR, Suster S, Thompson LD, Turk AT, Sadow PM, Urken ML, Wenig BM.

Thyroid. 2017 Dec;27(12):1498-1504. doi: 10.1089/thy.2017.0280. Epub 2017 Nov 7.

PMID:
29020884
39.

The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary.

Shen Z, Asa SL, Ezzat S.

Mol Cell Endocrinol. 2018 Feb 5;461:188-193. doi: 10.1016/j.mce.2017.09.013. Epub 2017 Sep 14.

PMID:
28919299
40.

Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma.

Mete O, Gucer H, Kefeli M, Asa SL.

Am J Surg Pathol. 2018 Feb;42(2):201-213. doi: 10.1097/PAS.0000000000000943.

PMID:
28877067
41.

Integrated Pathology Informatics Enables High-Quality Personalized and Precision Medicine: Digital Pathology and Beyond.

Volynskaya Z, Chow H, Evans A, Wolff A, Lagmay-Traya C, Asa SL.

Arch Pathol Lab Med. 2018 Mar;142(3):369-382. doi: 10.5858/arpa.2017-0139-OA. Epub 2017 Aug 29.

PMID:
28849944
42.

Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?

Parente DN, Kluijfhout WP, Bongers PJ, Verzijl R, Devon KM, Rotstein LE, Goldstein DP, Asa SL, Mete O, Pasternak JD.

World J Surg. 2018 Feb;42(2):321-326. doi: 10.1007/s00268-017-4182-5.

PMID:
28828746
43.

Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin.

Alshaikh OM, Yoon JY, Chan BA, Krzyzanowska MK, Butany J, Asa SL, Ezzat S.

Endocr Pathol. 2018 Mar;29(1):15-20. doi: 10.1007/s12022-017-9492-5.

PMID:
28718084
44.

The epigenetic landscape of differentiated thyroid cancer.

Asa SL, Ezzat S.

Mol Cell Endocrinol. 2018 Jul 5;469:3-10. doi: 10.1016/j.mce.2017.07.012. Epub 2017 Jul 12. Review.

PMID:
28711609
45.

Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications.

Ezzat S, Cheng S, Asa SL.

Mol Cell Endocrinol. 2018 Jul 5;469:70-76. doi: 10.1016/j.mce.2017.07.011. Epub 2017 Jul 12. Review.

PMID:
28711607
46.

Clinical Applications of Whole-slide Imaging in Anatomic Pathology.

Volynskaya Z, Evans AJ, Asa SL.

Adv Anat Pathol. 2017 Jul;24(4):215-221. doi: 10.1097/PAP.0000000000000153. Review.

PMID:
28590953
47.

The evolution of differentiated thyroid cancer.

Asa SL.

Pathology. 2017 Apr;49(3):229-237. doi: 10.1016/j.pathol.2017.01.001. Epub 2017 Mar 7. Review.

PMID:
28279477
48.

From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.

Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER Jr, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J; attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016.

Endocr Relat Cancer. 2017 Apr;24(4):C5-C8. doi: 10.1530/ERC-17-0004.

PMID:
28264912
49.

Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS; Cancer Genome Atlas Research Network, Pacak K, Nathanson KL, Wilkerson MD.

Cancer Cell. 2017 Feb 13;31(2):181-193. doi: 10.1016/j.ccell.2017.01.001. Epub 2017 Feb 2.

50.

Pituitary acromegaly: not one disease.

Asa SL, Kucharczyk W, Ezzat S.

Endocr Relat Cancer. 2017 Mar;24(3):C1-C4. doi: 10.1530/ERC-16-0496. Epub 2017 Jan 25.

PMID:
28122798

Supplemental Content

Support Center